Sanofi has agreed to acquire Blueprint Medicines for $9.1 billion, expanding its footprint in rare immunological diseases. The purchase includes a 27% premium per share and could total nearly $9.5 ...

Shares of Blueprint Medicines Corp. (NASDAQ:BPMC) soared 26.5% after Sanofi (NASDAQ:SNY) revealed plans to acquire the biopharmaceutical company in a deal valued at approximately $9.5 billion. The ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi SAN-0.71%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC-0.05%decrease; red down pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

Blueprint Medicines Corporation (NASDAQ: BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint ...

The Department of Health – Abu Dhabi (DoH) and Sanofi have signed a memorandum of understanding (MoU) to bolster vaccine ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...